Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyProvidence COVID-19 Testing Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedProvidence Health PlanPolicy 350

    COVID-19 Testing

    Customize your policy alerts

    Sign up for Providence Health Plan Policy 350 alerts

    Get alerted when Policy 350 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Commercial coverage of SARS-CoV-2 molecular, antigen, and antibody testing for individualized diagnosis, pre-procedural testing, and certain COVID-19-related conditions.

    Policy Summary
    PayerProvidence Health Plan
    PolicyCOVID-19 Testing
    Policy CodePolicy 350
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateOct 1, 2027
    Key ActionDocument the attending provider’s individualized assessment that testing is medically appropriate for the individual.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Over-the-counter COVID-19 testing is not covered as of July 1, 2023.

    Separate high-throughput COVID-19 testing codes U0003-U0005 terminated on May 11, 2023.

    COVID-19 testing encounters, including preoperative testing, should generally be coded with Z20.822 rather than Z11.52 during the pandemic.

    Claims billed with CPT 87913 for research-related testing will not be reimbursed.

    The November 2026 revision was an annual update with no changes to coverage criteria.

    4Required criteria for molecular or antigen testing
    Jul 1, 2023Over-the-counter testing not covered from
    May 11, 2023High-throughput codes terminated
    87913Research testing code not reimbursed
    11COVID-19 testing codes listed

    Coverage Criteria

    Antigen and Molecular Testing

    Molecular or antigen testing for SARS-CoV-2 is medically necessary when ALL of the following criteria are met:

    ALL of the following

    • Testing is primarily intended for individualized diagnosis of COVID-19 or for pre-procedural testing; claims for pre-procedural testing should use the correct diagnosis code, such as Z208.22, to support proper claims payment.
    • Testing is ordered by a licensed or otherwise authorized health care provider acting within the scope of the provider's license or authorization.
    • The test is FDA approved or has an Emergency Use Authorization (EUA).
    • Testing is performed by a CLIA-accredited laboratory or is CLIA-waived as indicated in the test instructions for use.

      The Plan may request the applicable CLIA certification or waiver and the manufacturer and name of the test performed.

    Antibody Testing

    Antibody testing may be medically necessary when ALL applicable criteria are met:

    ALL of the following

    • The molecular or antigen testing criteria above are met.
    • Results will be used to diagnose a condition related to COVID-19 infection, such as multisystem inflammatory syndrome in children (MIS-C).
    • The antibody test is not used as the sole basis for diagnosis.

      The FDA believes serological tests should not be used as the sole basis for diagnosis.

    Recurrent Testing

    High-frequency testing may be subject to medical-necessity review.

    ALL of the following

    • Testing is performed in accordance with the applicable molecular, antigen, or antibody testing criteria.
    • Medical records demonstrate that the testing was medically appropriate and performed in accordance with current accepted standards of medical practice.

      Records may be requested, particularly for multiple tests per day for a single member.

    Non-Covered, Non-Diagnostic Testing

    Antigen and antibody in vitro testing for SARS-CoV-2 is NOT medically necessary when the applicable diagnostic criteria are not met, including testing for any of the following purposes:

    ONE of the following

    • A purpose not primarily intended to diagnose an individual with COVID-19.
    • Public health surveillance testing, including epidemiologic research purposes; research-related testing billed with CPT 87913 is not reimbursed.
    • Employment or school purposes, including return-to-work or return-to-school programs, general workplace or school safety screening, work- or school-related travel, sports participation, pre-employment verification, routine physicals, or insurance purposes.
    • General screening, including travel, social requirements, community tracking, or determining the need for personal protective equipment.

    Diagnostic and Antibody Testing

    Diagnostic and serological testing is covered when ALL applicable statutory, authorization, and medical-necessity requirements are met:

    ALL of the following

    • The test is an in vitro diagnostic test for detection of SARS-CoV-2 or diagnosis of COVID-19, or is a serological test otherwise meeting the applicable statutory requirements.
    • The test is approved, cleared, or authorized under applicable provisions of the Federal Food, Drug, and Cosmetic Act, including section 510(k), 513, 515, or 564; is developed under an applicable emergency-use authorization pathway; is developed in and authorized by a state that has notified the HHS Secretary of its intent to review COVID-19 diagnostic tests; or is otherwise determined appropriate by the HHS Secretary in guidance.
    • An attending health care provider makes an individualized clinical assessment that testing is medically appropriate for the individual based on current accepted standards of medical practice.
    • The provider is licensed or otherwise authorized under applicable law, acts within the scope of the provider's license or authorization, and is responsible for providing care to the patient.

    At-Home Antigen Testing

    At-home COVID-19 testing is covered only when ALL applicable requirements are met:

    ALL of the following

    • The test is ordered by an attending health care provider who has determined that it is medically appropriate for the individual based on current accepted standards of medical practice.
    • The test otherwise meets the applicable statutory criteria under section 6001(a)(1) of the FFCRA, as amended by section 3201 of the CARES Act.
    • The test is an authorized, cleared, or approved diagnostic test, including a test involving self-collection of a specimen at home.

    Recurrent Diagnostic Testing

    When diagnostic-testing requirements are satisfied, recurrent testing has no stated numerical limit.

    ALL of the following

    • Each test is diagnostic and medically appropriate for the individual, as determined by an attending health care provider in accordance with current accepted standards of medical practice.
    • Providers consider applicable CDC guidance and guidance issued by state, tribal, territorial, and local health departments or professional societies when determining whether recurrent diagnostic testing is appropriate.

    Surveillance and Workplace Testing

    Outside the applicable FFCRA coverage scope

    • Testing to screen for general workplace health and safety, including employee return-to-work programs.
    • Public health surveillance for SARS-CoV-2, including epidemiologic research purposes.
    • Any purpose not primarily intended for individualized diagnosis or treatment of COVID-19 or another health condition.

    As of July 1, 2023, over-the-counter COVID-19 testing is not covered.

    This policy does not address panel testing for SARS-CoV-2 infection and COVID-19 diagnosis. See the Respiratory Viral Panels medical policies for applicable criteria: Respiratory Viral Panels, MP256 (Company), and Respiratory Viral Panels, MP255 (Medicare).

    Over-the-counter COVID-19 testing is not covered as of July 1, 2023, including at-home over-the-counter tests notwithstanding the earlier federal requirement for coverage of eight tests per covered individual per month beginning January 15, 2022.

    Workplace, return-to-work, school, surveillance, travel, social, community-tracking, and other testing purposes not primarily intended for individualized diagnosis or treatment are outside the applicable FFCRA coverage scope and are not covered as diagnostic testing under this policy.

    Research-related testing billed with CPT 87913 is not reimbursed.

    COVID-19 research-related testing billed with CPT 87913 is not reimbursed.

    Antigen and antibody testing is not medically necessary when the applicable individualized diagnostic, provider-order, authorization, laboratory, or other medical-necessity criteria are not met.

    FDA approval, clearance, or authorization alone does not establish medical necessity or serve as a basis for coverage. FDA Emergency Use Authorization allowed certain COVID-19 tests without traditional FDA approval; the FDA maintains listings of authorized serological tests for informational purposes.

    Covered Indications

    Individualized Diagnosis or Pre-procedural Molecular/Antigen Testing

    Molecular or antigen SARS-CoV-2 testing is covered for individualized diagnosis or pre-procedural testing when ALL of the following are met:

    Individualized diagnosis or pre-procedural testing

    • Purpose

      • Testing is primarily intended for individualized diagnosis of COVID-19.
      • Testing is performed for a pre-procedural purpose.
    • Authorization: The test is FDA approved or has an Emergency Use Authorization (EUA).
    • Laboratory requirement:

    Frequency and Quantity Considerations

    Frequency limits
    Testing typesSARS-CoV-2 antigen, molecular, or antibody testing
    Review triggerHigh-frequency testing, including multiple tests per day for a single member, may be subject to medical necessity review.
    DocumentationMedical records may be requested and must demonstrate that testing was performed in accordance with the applicable testing criteria.
    Frequency limits
    Numerical limitNo numerical limit is stated for diagnostic tests.
    Coverage conditionEach test must be diagnostic and medically appropriate for the individual.

    Coding and Diagnosis Codes

    Non-Covered, Non-Diagnostic TestingCPTNot Covered
    87913Public health surveillance testing, including epidemiologic research purposes
    Diagnosis Codes for Pre-Procedural TestingICD-10
    Z208.22Example diagnosis code for pre-procedural testing; the policy states that the correct diagnosis code should be billed to ensure proper claims payment
    COVID-19 laboratory testing and high-throughput technology codesmixed
    U0003COVID-19 high-throughput technology testing code; terminated May 11, 2023
    U0004COVID-19 high-throughput technology testing code; terminated May 11, 2023
    U0005COVID-19 high-throughput technology testing code; terminated May 11, 2023
    87635Existing generic CPT code identified as an anticipated code for high-throughput COVID-19 testing after termination of U0003-U0005
    U0002Existing generic code identified as an anticipated code for high-throughput COVID-19 testing after termination of U0003-U0005
    Not reimbursed research-related testingCPTNot Covered
    87913Research-related testing; claims billed with this code will not be reimbursed
    Allowable diagnosis codesICD-10Covered
    A084Viral intestinal infection, unspecified
    U071COVID-19
    Z20822Contact with and (suspected) exposure to COVID-19
    J03.90Acute tonsillitis, unspecified
    J029Acute pharyngitis, unspecified
    J069Acute upper respiratory infection
    J10.1Influenza due to other identified influenza virus with other respiratory manifestations
    J111Influenza due to unidentified virus with other respiratory manifestations
    J1282Pneumonia due to coronavirus disease 2019
    J208Acute bronchitis due to other specified organisms
    1–10 of 33
    1/4
    Not appropriate screening diagnosis codeICD-10Not Covered
    Z11.52Encounter for screening for COVID-19; not appropriate during the COVID-19 pandemic
    FDA and statutory authorization referencesmixed
    510(k)FDA approval or clearance pathway referenced for qualifying in vitro diagnostic tests
    513FDA statutory pathway referenced for qualifying in vitro diagnostic tests
    515FDA statutory pathway referenced for qualifying in vitro diagnostic tests
    564FDA emergency use authorization pathway referenced for qualifying in vitro diagnostic tests
    21 U.S.C. § 360(k)Federal statutory authority for FDA approval or clearance referenced in the test definition
    21 U.S.C. § 360cFederal statutory authority referenced in the test definition
    21 U.S.C. § 360eFederal statutory authority referenced in the test definition
    21 U.S.C. § 360bbb-3Federal statutory authority for emergency use authorization referenced in the test definition
    COVID-19 testing codes listedCPT
    0224UAntibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease COVID-19), includes titer(s), when performed; Mount Sinai Laboratory.
    0226USurrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease COVID-19), ELISA, plasma, serum.
    86408Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease COVID-19), single step method.
    86409Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease COVID-19); screen.
    86413Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease COVID-19); titer.
    86769Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease COVID-19), quantitative; multi-step method.
    87635Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease COVID-19), amplified.
    87811Infectious agent antigen detection by immunoassay with direct optical observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease COVID-19).
    U0001CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
    U00022019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes, non-CDC.
    COVID-19 testing HCPCS codesHCPCS
    U0001CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
    U00022019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes, non-CDC.
    Not reimbursed research-related testingCPTNot Covered
    87913Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation identification in targeted region(s); research-related testing.

    Provider and Billing Actions

    Prior Authorization

    Obtain authorization for unlisted services

    For potentially covered services addressed in this policy, obtain prior authorization before submitting an unlisted code to help avoid post-service denial.

    Documentation Required

    Submit complete claim and test documentation

    For pre-procedural testing, bill the appropriate diagnosis code, such as Z208.22, to support proper claims payment. Retain the applicable CLIA certification or waiver and the manufacturer and name of the test, because the Plan may request this information.

    Documentation Required

    Maintain records for high-frequency testing

    Ordering Requirements

    Note

    Use an authorized ordering provider

    Testing must be ordered by a licensed or otherwise authorized health care provider acting within the scope of the license or authorization. A licensed pharmacist enrolled in the state where services are rendered may order COVID-19 diagnostic testing when practicing within scope and as part of appropriate medical care determined by the attending health care provider.

    Definitions

    Definitions
    DefinitionAntigen tests are immunoassays that detect the presence of a specific viral antigen, indicating current viral infection.
    Authorized specimensAuthorized specimen types include nasopharyngeal, nasal swab, or saliva specimens placed directly into the assay's extraction buffer or reagent.
    Test formatsAuthorized antigen tests may be point-of-care, laboratory-based, or self-tests.
    Definitions
    DefinitionMolecular tests detect SARS-CoV-2 viral RNA by creating millions of copies of small segments of the virus.
    Detection characteristicAmplification allows even low levels of viral genetic material to be detected.

    Background

    COVID-19 is an infectious disease caused by SARS-CoV-2 and commonly presents with fever, cough, and shortness of breath. Antigen tests detect viral antigen and generally provide rapid results, while molecular tests detect amplified viral RNA and are usually more sensitive but may take a day or longer. Antibody tests detect an immune response to prior or recent infection and cannot diagnose a current infection.

    Policy Summary
    PayerProvidence Health Plan
    PolicyCOVID-19 Testing
    Policy CodePolicy 350
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateOct 1, 2027
    Key ActionDocument the attending provider’s individualized assessment that testing is medically appropriate for the individual.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsFrequency and Quantity ConsiderationsCoding and Diagnosis CodesProvider and Billing ActionsOrdering RequirementsNot Covered ServicesDefinitionsBackground
  1. A pharmacist may order COVID-19 diagnostic testing when licensed and enrolled in the state where services are rendered, practicing within the scope of the pharmacist's license, and participating in appropriate medical care as determined by the attending health care provider.
  2. For antibody testing, results will be used to diagnose a condition related to current or past SARS-CoV-2 infection, and the serological test is not used as the sole basis for diagnosis.
  3. For recurrent diagnostic testing, each test is diagnostic and medically appropriate for the individual; there is no stated numerical limit when these requirements are satisfied.

    Providers are urged to consult CDC guidance and guidance from state, tribal, territorial, and local health departments or professional societies.

  4. Testing is performed by a CLIA-accredited laboratory or is CLIA-waived as indicated in the test instructions for use.
  5. Ordering and clinical responsibility: Testing is ordered by a licensed or authorized health care provider responsible for providing care to the patient and acting within the scope of the provider's license or authorization.
  6. Diagnosis of a COVID-19-related Condition Using Antibody Testing

    Antibody testing for a COVID-19-related condition is covered only when ALL of the following are met:

    Diagnosis of a COVID-19-related condition using antibody testing

    • The applicable molecular or antigen testing criteria are met, including the covered purpose, qualified ordering provider, regulatory authorization, and laboratory requirements.
    • The antibody test results will be used to diagnose a condition related to COVID-19 infection, such as multisystem inflammatory syndrome in children (MIS-C).
    • Antibody testing is not used as the sole basis for diagnosis.

    Individualized Diagnosis or Treatment

    Testing for individualized diagnosis or treatment is covered when ALL applicable requirements are met:

    Individualized diagnosis or treatment

    • Qualifying testing pathway

      • The SARS-CoV-2 diagnostic or serological test meets an applicable statutory authorization pathway, including FDA approval, clearance, or authorization; an appropriate EUA pathway; qualifying state authorization; or HHS determination.
      • The test is an at-home test that is ordered by an attending health care provider, determined medically appropriate for the individual, and meets the statutory criteria in section 6001(a)(1) of the FFCRA.
      • The serological or antibody test otherwise meets the applicable requirements for an in vitro diagnostic test.
    • Individualized medical assessment: An attending health care provider determines through an individualized clinical assessment that testing is medically appropriate for the individual in accordance with current accepted standards of medical practice.
    • Qualified ordering provider: The ordering provider is licensed or otherwise authorized under applicable law and acts within the scope of the provider's license or authorization.

      A qualifying pharmacist may order diagnostic testing when permitted by law and when the testing is part of appropriate medical care determined by the attending provider.

    Allowable Diagnosis Scenarios

    Use diagnosis coding that accurately reflects the documented clinical scenario and follows the ICD-10-CM Official Guidelines. Covered testing may be supported by any of the following scenarios:

    Allowable diagnosis scenarios

    • Documented active COVID-19 infection, including a provider-documented diagnosis or positive COVID-19 test result.
    • Documented contact with or suspected exposure to COVID-19.
    • Compatible respiratory symptoms or conditions, including cough, fever, shortness of breath, wheezing, acute respiratory infection, bronchitis, pneumonia, respiratory failure, or related conditions.
    • Personal history of COVID-19 or follow-up after completed treatment.
    • Examination for antibody response.
    • Multisystem inflammatory syndrome.
    • Post-COVID-19 condition.
    • Viral disease complicating pregnancy, childbirth, or the puerperium.
    • Congenital viral disease.
    Provider determination
    An attending health care provider must determine medical appropriateness in accordance with current accepted standards of medical practice.
    Over-the-counter testing
    Historical allowanceEight FDA-authorized over-the-counter at-home tests per covered individual per month.
    Historical effective dateThe federal requirement began January 15, 2022.
    Current policy statusOver-the-counter COVID-19 testing is not covered as of July 1, 2023.

    For high-frequency testing subject to medical necessity review, maintain medical records demonstrating that testing met the applicable antigen, molecular, or antibody testing criteria.

    Documentation Required

    Document individualized medical necessity

    Document the attending health care provider’s individualized clinical assessment that testing is medically appropriate for the individual and consistent with current accepted standards of medical practice. For recurrent testing, document the medical appropriateness of each diagnostic test.

    Documentation Required

    Verify ordering provider qualifications

    Document that the ordering provider is licensed or otherwise authorized under applicable law, acts within the scope of the license or authorization, and is responsible for providing care to the patient.

    Billing Rule

    Use diagnosis codes that match the record

    Submit diagnosis coding that accurately reflects the patient’s documented condition, exposure, symptoms, antibody-testing purpose, post-COVID condition, pregnancy or newborn status, and associated manifestations.

    Note

    Expect claim-level review of unlisted codes

    Unlisted codes are reviewed at the claim level for medical necessity, correct coding, and pricing.

    Billing Rule

    Confirm contract and member eligibility

    Coding remains subject to provider contracts, member benefits, eligibility, and potential utilization audit. Inclusion or omission of a code does not imply or guarantee reimbursement or coverage.

    Denial Risk

    Avoid non-diagnostic or general screening use

    Antigen or antibody SARS-CoV-2 testing is not medically necessary when the applicable diagnostic criteria are not met, including testing for surveillance, employment or school requirements, travel, social requirements, community tracking, sports participation, routine physicals, insurance purposes, or determining the need for personal protective equipment.

    Denial Risk

    Support high-frequency testing

    High-frequency SARS-CoV-2 antigen, molecular, or antibody testing, such as multiple tests per day for one member, may undergo medical necessity review. Medical records must demonstrate that testing was performed in accordance with the applicable testing criteria.

    Denial Risk

    Over-the-counter testing is not covered

    Over-the-counter COVID-19 testing is not covered as of July 1, 2023.

    Denial Risk

    Meet statutory and diagnostic-test criteria

    Testing that does not meet the statutory definition and criteria for an in vitro diagnostic test for SARS-CoV-2 detection or COVID-19 diagnosis may not be covered. Over-the-counter COVID-19 testing is not covered as of July 1, 2023.

    Denial Risk

    Do not bill surveillance or workplace testing

    Testing performed for general workplace health and safety, employee return-to-work programs, public-health surveillance, or another purpose not primarily intended for individualized diagnosis or treatment is outside the applicable coverage scope.

    Denial Risk

    FDA status alone does not establish coverage

    FDA approval, clearance, or authorization alone does not establish medical necessity or serve as a basis for coverage. The testing must also satisfy the applicable coverage criteria and be medically appropriate for the individual.

    Denial Risk

    Do not bill CPT 87913 for research testing

    Claims billed with CPT 87913 for research-related testing will not be reimbursed.

    Denial Risk

    CPT 87913 COVID-19 research claims are not reimbursed

    Claims billed with CPT code 87913 for research-related COVID-19 testing will not be reimbursed.

    Denial Risk

    Non-covered services billed with unlisted codes will be denied

    An unlisted code submitted for a non-covered service addressed by this policy will be denied as not covered.

    Billing Rule

    Check NCCI and MUE edits

    Claims remain subject to National Correct Coding Initiative procedure-to-procedure bundling edits and medically unlikely edits, including applicable daily maximums.

    Testing settingMost molecular tests are performed in a laboratory because of the complexity and sensitivity of the process.
    Definitions
    DefinitionSerological tests detect antibodies such as IgM or IgG generated in response to an infection.
    Clinical roleSARS-CoV-2 antibody tests are supplemental aids for identifying an adaptive immune response and indicating recent or prior infection.
    Current infectionSerology tests cannot be used to diagnose a current infection.
    Definitions
    QualificationAn individual licensed or otherwise authorized under applicable law.
    Scope of practiceThe provider must act within the scope of the provider's license or authorization.
    Clinical responsibilityThe provider is responsible for providing care to the patient and makes an individualized assessment that testing is medically appropriate.
    Pharmacist orderingA pharmacist licensed and enrolled in the state where services are rendered may order COVID-19 diagnostic testing when practicing within the scope of the license and as part of appropriate medical care determined by the attending provider.
    Definitions
    PurposeAn in vitro diagnostic test detects SARS-CoV-2 or diagnoses COVID-19, including administration of the test.
    FDA authorizationThe test is approved, cleared, or authorized under section 510(k), 513, 515, or 564 of the Federal Food, Drug, and Cosmetic Act.
    Other qualifying pathwaysThe test may qualify through an emergency-use-authorization request, authorization by a qualifying state, or a determination by the HHS Secretary that the test is appropriate.
    Definitions
    QualificationAn attending provider is an individual licensed or otherwise authorized under applicable law and acting within the scope of the license or authorization.
    Clinical assessmentThe provider makes an individualized clinical assessment that testing is medically appropriate in accordance with current accepted standards of medical practice.
    Direct care requirementThe provider need not be directly responsible for providing care to the patient to be considered an attending provider.
    Pharmacist orderingA licensed and enrolled pharmacist may order COVID-19 diagnostic testing within the scope of the license when it is part of appropriate medical care determined by the attending provider.